AUPH News and Press, Aurinia Pharmaceuticals Inc From 08/21/23

Dr. Karen Smith and Jeffrey A. Bailey joined Aurinia’s Board of Directors August 18, 2023 Dr. Daniel G. Billen appointed Chair of the Board of Directors Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that...

2023-08-03 12:32:02 ET Aurinia Pharmaceuticals Inc. (AUPH) Q2 2023 Earnings Conference Call August 3, 2023, 8:30 AM ET Company Participants Jamie Harrell - Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer Con...

2023-08-03 06:40:52 ET More on Aurinia Pharma Aurinia: Strategic Alternatives Could Go Either Way For Stakeholders Aurinia Pharmaceuticals: Still In The Game With Lupkynis Sales Aurinia: Despite Milder Shareholder Vote, A Bid To Sell Is Still Not Over Aurinia...

2023-08-03 06:02:12 ET Aurinia Pharma press release ( NASDAQ: AUPH ): Q2 GAAP EPS of -$0.08 beats by $0.11 . Revenue of $41.49M (+47.2% Y/Y) beats by $3.98M . Increases 2023 revenue guidance range to $150 - $160 million from net product sales of LUPKYNIS ...

Net revenue increased to $41.5 million for second quarter of 2023; 47% over the prior year second quarter Increases 2023 revenue guidance range to $150 - $160 million from net product sales of LUPKYNIS ® (voclosporin) Conference call to be hosted today at 8:30 a.m...

2023-08-02 13:39:36 ET Aurinia Pharma ( NASDAQ: AUPH ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus Revenue Estimate is $37.51M (+33.0% Y/Y). Over the last ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2023, on Thursday, August 3, 2023, before markets open. Aurinia’s management team will host a conference call/webcast at 8:3...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that full results from the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published online in Arthritis & Rheumatology , the official peer-reviewed journal of the American College...

2023-07-18 12:50:45 ET Summary Aurinia Pharmaceuticals has reported increased Q1 2023 net revenue of $34.4 million, largely due to higher sales of its Lupus Nephritis drug, Lupkynis. However, the company also recorded a net loss of $26.2 million. The company is exploring strategic...

2023-06-30 14:49:03 ET Shares of the autoimmune specialist Aurinia Pharmaceuticals (NASDAQ: AUPH) rose by as much as 13.2% in early morning trading Friday. The biotech's shares cooled off after their hot start and are up by 8.6% on heavy volume as of 1:41 p.m. ET Friday. The sto...